The 70-gene prognostic signature for korean breast cancer patients

Journal of Breast Cancer

Volumn 14, Issue 1, 2011, Pages 33-38

  Na, Kuk Young ^a   Kim, Ku Sang ^a   Lee, Jeong Eon ^b   Kim, Hee Jeong ^c   Yang, Jung Hyun ^b   Ahn, Sei Hyun ^c   Moon, Byung In ^d   Kim, Ra Mi ^a   Ko, Si Mon ^a   Jung, Yong Sik ^a  

^a Ajou University School of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Mokdong Hospital   (South Korea)

Author keywords

Breast neoplasms; Gene expression profiling; Korea

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CLINICAL ARTICLE; DIAGNOSTIC TEST; FEMALE; GENE EXPRESSION PROFILING; GENETIC DIFFERENCE; HUMAN; HUMAN TISSUE; PRACTICE GUIDELINE; PROGNOSIS; RISK ASSESSMENT; TUMOR GENE; VALIDATION STUDY;

EID: 79955439208     PISSN: 17386756     EISSN: None     Source Type: Journal    
DOI: 10.4048/jbc.2011.14.1.33     Document Type: Article

References (24)

1. National Cancer Center, Korea Central Cancer Registry. 2006 Annual Report of the Korea Central Cancer Registry. Seoul: Ministry of Health and Welfare; 2007. p. 1-114.
2. Korea Breast Cancer Society. Breast Cancer Facts and Figures 2006-2008. Seoul: Korean Breast Cancer Society; 2008.
3. Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351: 1451-1467.
4. Early Breast Cancer Trialists Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352:930-942.
5. Korean Breast Cancer Society Nationwide Korean breast cancer data of 2004 using breast canser registration program. J Breast Cancer 2006;9: 151-161.
6. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-536.
7. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006;98:1183-1192.
8. Bueno-de-Mesquita JM, Linn SC, Keijzer R, Wesseling J, Nuyten DS, van Krimpen C, et al. Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat 2009; 117:483-495.
9. Mook S, Schmidt MK, Viale G, Pruneri G, Eekhout I, Floore A, et al. Te 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study Breast Cancer Res Treat 2009; 116:295-302.
10. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
11. Ishitobi M, Goranova TE, Komoike Y, Motomura K, Koyama H, Glas AM, et al. Clinical utility of the 70-gene MammaPrint profle in a Japanese population. Jpn J Clin Oncol 2010;40:508-512.
12. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer.I.Te value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-410.
13. Hauser-Kronberger C, Dandachi N. Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer. J Mol Histol 2004;35:647-653.
14. Glas AM, Floore A, Delahaye LJ, Witteveen AT, Pover RC, Bakx N, et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test BMC Genomics 2006;7:278.
15. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Turlimann B, Senn HJ Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003;21:3357-3365.
16. National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer. November 1-3,2000. J Natl Cancer Inst Monogr 2001;(30):5-15.
17. Hellekson KL. NIH statement on adjuvant therapy for breast cancer. Am Fam Physician 2001;63:1857-15,61.
18. Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, et al.Population-based validation of the prognostic model ADJUVANT!for early breast cancer. J Clin Oncol 2005;23:2716-2725.
19. Ravdin PM, Siminof LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. JClinOncol 2001;19:980-991.
20. Early Breast Cancer Trialists Collaborative Group (EBCTCG). Efectsof chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717.
21. Bueno-de-Mesquita JM, van Harten WH, Retel VP, van't Veer LJ, van Dam FS, Karsenberg K, et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol 2007;8:1079-1087.
22. Wittner BS, Sgroi DC, Ryan PD, Bruinsma TJ, Glas AM, Male A, et al.Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort Clin Cancer Res 2008; 14:2988-2993.
23. Straver ME, Glas AM, Hannemann J, Wesseling J, van de Vijver MJ, Rutgers EJ, et al. Te 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2010; 119:551-558.
24. Botha JL, Bray F, Sankila R, Parkin DM. Breast cancer incidence and mortality trends in 16 European countries. Eur JCancer 2003;39:1718-1729.